Arrowhead Pharmaceuticals, Inc. (ETR:HDP1)

Market Cap	10.54B +340.1%
Revenue (ttm)	586.01M +16.8%
Net Income	-280.06M
EPS	-2.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2
Open	74.62
Previous Close	74.34
Day's Range	74.62 - 74.62
52-Week Range	60.74 - 78.04
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 4, 2026

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 711
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: HDP1

Financial Performance

In fiscal year 2025, Arrowhead Pharmaceuticals's revenue was $829.45 million, an increase of 23258.15% compared to the previous year's $3.55 million. Losses were -$1.63 million, -99.73% less than in 2024.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 24, 2026

Data Sources Report a data error